SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Federal government weighs in on antibiotic resistance Issues national strategy and calls for alternative treatments

A protein can speed up recovery after radiation and chemo Shows promise in animal experiments

Patient engagement solutions market expected to soar Will hit $13.7 billion by 2019

Big data platform designed for new value-based model Helps physicians improve outcomes while reducing costs

Hospitals saving billions on charity care ACA may save expansion state hospitals up to $4.2 billion in 2014

FDA approves GE's new PET/CT Higher sensitivity and field-of-view

Consensys joins forces with Oncology Services International A strategic alliance among ISOs

Checking in with the first installed MEVION S250 Assessing nine months of single room proton therapy

MEDICA 2014: IT Matters at MEDICA Health IT takes center stage at a number of presentations

Scripps' pencil-beam proton center had "exceptional results" Treated more tumor sites in seven months than others have

Varian backs radiosurgery vs. traditional surgery study

by Brendon Nafziger , DOTmed News Associate Editor
Varian Medical Systems said last week it's contributing funds to help with patient accrual efforts for a National Cancer Institute-sponsored, multi-center study comparing radiosurgery against the knife-based kind for high-risk patients with early-stage lung cancer.

A Varian spokeswoman told DOTmed News the Sunnyvale, Calif-based company will kick in some funds and provide other help to support the study's goal of accruing 420 patients over a five-year period. As of June, 45 centers had qualified to participate in the phase III trial, the company said.

Story Continues Below Advertisement

Stretcher pads & mattress discounts for DOTmed users, call (800)448-6163

North America Mattress Corp. offers best pricing for replacement pads and mattresses. Buy direct from the manufacture and save.



The NCI-financed project is being run by the Alliance for Clinical Trials in Oncology, a one-year-old collaboration among three cancer research organizations: the American College of Surgeons Oncology Group, Cancer and Leukemia Group B and North Central Cancer Treatment Group.

Formally known as ACOSOG Z4099/RTOG 1021, the study seeks to compare whole-body stereotactic radiosurgery, which uses higher doses of radiation in fewer fractions, against sublobar resection, the surgical removal of part of the lobe of the lung, for high-risk patients with non-small cell lung cancer whose cancer is operable.

"To date, there have not been any prospective, randomized trials to compare the efficacy and toxicity of surgery to radiosurgery for high-risk operable early-stage lung cancer patients," Kolleen Kennedy, president of Varian's oncology systems business, said in a statement. "We anticipate that this trial could yield very useful information for making treatment decisions about these types of cases."

According to a "talking points" document hosted on ACOSOG's website, an earlier study involving radiosurgery performed on patients with medically inoperable early-stage lung cancer achieved 56 percent survival rates after three years, double the reported rates for conventional radiation therapy. The researchers are hoping for higher survival rates in the high-risk operable population involved in the current study.

Varian makes the TrueBeam STx and the Trilogy Tx radiosurgery devices.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED